European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
February 13, 2024 02:30 ET
|
CRISPR Therapeutics AG
—Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:...
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024 16:01 ET
|
CRISPR Therapeutics AG
- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR...
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
January 08, 2024 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
December 04, 2023 16:15 ET
|
CRISPR Therapeutics AG
-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 06, 2023 16:15 ET
|
CRISPR Therapeutics AG
-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act...
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
November 06, 2023 05:01 ET
|
CRISPR Therapeutics AG
-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- -CTX320™ led to durable reductions of...
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
October 31, 2023 17:53 ET
|
CRISPR Therapeutics AG
-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today...
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
October 31, 2023 07:05 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
October 16, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...